FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 332 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... October 4, 2021 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Load more HOT NEWS New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma What Is Scanxiety? How People With Cancer and Survivors Can Cope The Cancer Moonshot: A Midpoint Progress Update Can Age Affect Response to Immune Checkpoint Inhibitors?
